Drug intelligence / Profile preview

BM003

Development stage: Preclinical
Lead developer: BIMINI Biotech

Overview

BM003 is a preclinical-stage therapeutic candidate being developed by BIMINI Biotech, a Dutch biopharmaceutical company. As of early 2021, the program is in the discovery or preclinical phase of development, with its specific molecular target, mechanism of action, and primary therapeutic indications yet to be publicly disclosed. BIMINI Biotech generally focuses on developing innovative therapies for oncology and age-related diseases, primarily through the modulation of growth factor signaling pathways such as the Growth Hormone Receptor (GHR) and Wnt signaling.

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on BM003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM003.

Explore the full profile